ストックスクリーナーアプリを入手
12.97
1.22%
-0.16
アフターアワーズ：
12.96
-0.010
-0.08%
前日終値:
$13.13
開ける：
$13.11
24時間の取引高:
729.62K
Relative Volume:
1.40
時価総額：
$790.78M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-10.55%
1か月 パフォーマンス:
+24.71%
6か月 パフォーマンス:
-45.55%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$12.70
$13.61
1週間の範囲:
$11.59
$14.40
52週間の値動き範囲:
$8.91
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
BCAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
12.97 | 790.78M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-17 | 開始されました | Wells Fargo | Underweight |
| 2025-02-06 | 開始されました | Wedbush | Outperform |
| 2024-12-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
| 2024-10-08 | 開始されました | Stifel | Buy |
| 2024-10-08 | 開始されました | TD Cowen | Buy |
すべてを表示
Bicara Therapeutics Inc (BCAX) 最新ニュース
Bicara Therapeutics Inc (NASDAQ: BCAX) Metrics That Matter Right Now - Stocksregister
Wells Fargo & Company MN Purchases New Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
MetLife Investment Management LLC Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Invesco Ltd. Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.43 - Defense World
A new trading data show Bicara Therapeutics Inc (BCAX) is showing positive returns. - Sete News
Legal & General Group Plc Acquires New Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc [BCAX] Shares Fall -3.43 % on Wednesday - knoxdaily.com
A closer look at Bicara Therapeutics Inc (BCAX)’s stock price trends - uspostnews.com
Wedbush Lifts Earnings Estimates for Bicara Therapeutics - Defense World
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities - TipRanks
Cautious Outlook on Bicara Therapeutics Inc. Amid Efficacy and Safety Concerns for Ficerafusp - TipRanks
Promising Clinical Trial Results Boost Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewswire
Riding the Waves: A Guide to Investing in BCAX Stock - investchronicle.com
JPMorgan Chase & Co. Buys 64,010 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Here’s Why - Defense World
Bicara Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Bicara Therapeutics Inc (NASDAQ: BCAX) Is The Among Hot Stock Right Now - Stocksregister
Geode Capital Management LLC Acquires 418,003 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara to present updated trial data at ASCO Meeting - Investing.com
Bicara to present updated trial data at ASCO Meeting By Investing.com - Investing.com South Africa
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Bicara Therapeutics to Present Updated Phase 1/1b Clinical Trial Data for Ficerafusp Alfa at ASCO 2025 - Nasdaq
Bicara Therapeutics (NASDAQ:BCAX) Research Coverage Started at Wells Fargo & Company - The AM Reporter
Bicara Stock: Innovative Precision Tumor Targeting (NASDAQ:BCAX) - Seeking Alpha
Wells Fargo & Company Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
Vanguard Group Inc. Acquires 1,020,528 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics initiated with an Underweight at Wells Fargo - TipRanks
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target - marketscreener.com
Corebridge Financial Inc. Takes $167,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
HC Wainwright Issues Pessimistic Forecast for BCAX Earnings - Defense World
Promising Developments and Market Opportunities Drive Buy Rating for Bicara Therapeutics - TipRanks
HC Wainwright Issues Pessimistic Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - The AM Reporter
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $36.67 Average Target Price from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Given New $44.00 Price Target at HC Wainwright - Defense World
Bicara stock price target lowered to $44 at H.C. Wainwright By Investing.com - Investing.com Canada
Bicara stock price target lowered to $44 at H.C. Wainwright - Investing.com
Buy Rating Affirmed for Bicara Therapeutics Inc. Amid Promising Clinical Data and Financial Stability - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.2%Should You Sell? - MarketBeat
FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock By Investing.com - Investing.com UK
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks
Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World
Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks
Bicara Therapeutics Inc (BCAX) 財務データ
Bicara Therapeutics Inc (BCAX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):